On January 10, 2025, Scorpion Capital issued a short seller report on TransMedics. Specifically, the report alleged wrongdoing with respect to TransMedics’ business practices, including fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The report also highlighted ongoing regulatory scrutiny, with reports of investigations by the DOJ, IRS, and state attorney generals into Medicare fraud linked to organ acquisition costs. Additionally, the report makes claims regarding customer dissatisfaction, including prominent transplant centers discontinuing their use of TransMedics’ devices citing concerns over their clinical value.
In response, the price of TransMedics’ stock has fallen by more than 13% over multiple trading days.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.